Dr. Pansick is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12200 Park Central Dr
Ste 180
Dallas, TX 75251Phone+1 214-320-8785Fax+1 214-645-2011
Summary
- Dr. Andrew Pansick is an ophthalmologist based in Dallas, TX. He completed his ophthalmology residency at Nassau University Medical Center in 2021 and graduated from the University of Texas Southwestern Medical School in 2017. He also completed an internship in internal medicine at MedStar Health/Georgetown-Washington Hospital Center. Dr. Pansick has several publications, including research on novel treatments in ophthalmology and studies on diabetic retinopathy and endophthalmitis prevention, with one of his works being widely cited.
Education & Training
Nassau University Medical CenterResidency, Ophthalmology, 2018 - 2021
MedStar Health/Georgetown-Washington Hospital CenterInternship, Internal Medicine, 2017 - 2018
University of Texas Southwestern Medical SchoolClass of 2017
Certifications & Licensure
TX State Medical License 2021 - 2026
DC State Medical License 2017 - 2018- American Board of Ophthalmology Ophthalmology
Publications & Presentations
PubMed
- Evaluation of a novel treatment, selenium disulfide, in killing Demodex folliculorum in vitro.Joshua Heczko, Carson Schell, Andrew Pansick, Rebecca Stein, Henry D Perry
Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie. 2023-10-01 - 11 citationsEnantioselective Halolactonization Reactions using BINOL-derived Bifunctional Catalysts: Methodology, Diversification, and ApplicationsDaniel W. Klosowski, J. Caleb Hethcox, Daniel H. Paull, Chao Fang, James R. Donald
The Journal of Organic Chemistry. 2018-05-02 - 5 citationsTOWARDS A TREATMENT FOR DIABETIC RETINOPATHY: Intravitreal Toxicity and Preclinical Safety Evaluation of Inducible Nitric Oxide Synthase Inhibitors.B. Cameron Carr, Caitlyn E. Emigh, Lea D Bennett, Andrew D. Pansick, David G. Birch
Retina. 2017-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
